激情综合啪啪6月丁香,久久久久国产精品91福利,99精品日韩欧美在线观看,91成人午夜福利在线观看国产

上海瑞齊生物科技有限公司

Anti-PAR4 抗體說明書

時(shí)間:2014-1-22閱讀:804
分享:

Mouse Anti-PAR4 抗體說明書antibody

Cat. Number: Rs-1196R

Quantity size: 0.1ml (dilute with pH 7.4 0.01 M PBS or diluent of antibody)

background:
The tumor suppressor WT1 represses and activates transcription. The protein encoded by this gene is a WT1-interacting protein that itself functions as a transcriptional repressor. It contains a putative leucine zipper domain which interacts with the zinc finger DNA binding domain of WT1. This protein is specifically upregulated during apoptosis of prostate cells. [provided by RefSeq, Jul 2008]Mouse Anti-PAR4 抗體說明書antibody

 

Specificity: · anti-PAR4 is a mouse monoclonal antibody unconjugated

· specific for anti-PAR4 of human,rat

· use for western blotting, elisa, immunoprecipitation

and immunohistochemistry

· Protein A affinity chromatography purification, purity :>95%

· Isotype: IgG

· mol wt: 37 kDa

 

Application: · Western blotting: 1:100-500

· Immunohistochemistry: 1:100-500

· ELISA: 1:500-1000

· Optimal working dilutions must be determined by the end user.

 

Storage: Store at –20 ºC for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20ºC. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ºC.

 

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.Mouse Anti-PAR4 抗體說明書antibody

 

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗(yàn)證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~

以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),環(huán)保在線對此不承擔(dān)任何保證責(zé)任。

溫馨提示:為規(guī)避購買風(fēng)險(xiǎn),建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。

在線留言
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |